Uterine Cervical NeoplasmsNCT06897306
Gastric-type Endocervical Adenocarcinoma: a Population-based Cohort Study
An observational study of Uterine Cervical Neoplasms and Surgery, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University at 1 site in China.
Trial summary
This study aims to collect data of patients with Gastric-type Endocervical Adenocarcinoma from the SEER database, analyze the related prognostic factors and treatment patterns of Gastric-type Endocervical Adenocarcinoma, and explore the impact of surgical treatment on the prognosis of locally advanced Gastric-type… Read more about this study
- Who is it for?
- Any age, women only
- Conditions the study is for
- Uterine Cervical Neoplasms, Surgery, Therapy
- What is being tested?
- surgery
- Type of treatment
- Surgery or procedure
- How many people
- 317 participants
- Where
- 1 siteChina
- Study dates
- 1 Oct 2024to 20 Jan 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- Women only
- No healthy volunteers
- Child, Adult, Older adult
Study population: The Surveillance, Epidemiology, and End Results (SEER) database is a comprehensive source of population - based cancer incidence and survival data in the United States. The population covered by the SEER database is diverse and representative of the broader U.S. population. It includes individuals from various racial and ethnic backgrounds, age groups, and geographic regions. The data are collected from 17 population - based cancer registries, which cover approximately 28% of the U.S. population. This allows for the analysis of cancer - related outcomes and trends across different demographic and socioeconomic groups, providing valuable insights into the burden of cancer and the effectiveness of cancer - related interventions in a population - based setting.
Who may be able to join
- Patients diagnosed with Gastric - type Endocervical Adenocarcinoma were identified using the SEER database and SEER*Stat 8.4.2 software. The search scope was the "SEER Research Plus Data, 17 Registries, Nov 2021 sub (2000 - 2019)" database. The screening criteria included "Site and Morphology, Analytic Behavior Recode = Malignant" and "Site and Morphology, ICD - O - 3 / WHO 2008 Recode Site = Cervix". Patients with Gastric - type Endocervical Adenocarcinoma in the database were selected.
Who cannot join
- Patients with a survival time of 0 or unknown.
Trial locations and contacts
1 site in 1 country.
China1 site
The Sun Yat-Sen Memorial Hospital of Sun Yat-Sen Universit
Guangzhou, Guangdong
About this study
Official title: Surgery Significantly Improves the Prognosis of Locally Advanced Gastric-type Endocervical Adenocarcinoma: a Population-based Cohort Study
This study aims to collect data of patients with Gastric-type Endocervical Adenocarcinoma from the SEER database, analyze the related prognostic factors and treatment patterns of Gastric-type Endocervical Adenocarcinoma, and explore the impact of surgical treatment on the prognosis of locally advanced Gastric-type Endocervical Adenocarcinoma.
Read the detailed description
This study aims to collect data of patients with Gastric - type Endocervical Adenocarcinoma from the SEER database, analyze the related prognostic factors and treatment patterns of patients with Gastric - type Endocervical Adenocarcinoma, and explore the impact of surgical treatment on the prognosis of locally advanced Gastric - type Endocervical Adenocarcinoma.
Study subjects: Patients diagnosed with Gastric - type Endocervical Adenocarcinoma were identified using the SEER database and SEER*Stat 8.4.2 software. The search scope was the "SEER Research Plus Data, 17 Registries, Nov 2021 sub (2000 - 2019)" database, and the screening criteria included "Site and Morphology, Analytic Behavior Recode = Malignant" and "Site and Morphology, ICD - O - 3 / WHO 2008 Recode Site = Cervix". Patients with cervical Gastric - type Endocervical Adenocarcinoma were selected from the database.
Outcome measures: Overall survival (OS): The time from diagnosis to death of the patient.
- Being tested
- surgery
- Keywords
- Uterine Cervical Neoplasms, cervical cancer, Gastric - type Mucinous Adenocarcinoma, surgery
- Medical subject headings
- Uterine Cervical Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
surgeryProcedure or surgery
The patient underwent surgery.
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall survival (OS)
The time from diagnosis to death of the patient.
Measured: The time from diagnosis to death of the patient，Assessed up to 227 months
Secondary outcomes (1)
Vital status recode(study cutoff used)
Any patient that dies after the follow-up cut-off date is recoded to alive as of the cut-off date.
Measured: up to 227 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Mar 2025
- Study start1 Oct 2024
- Primary completion1 Nov 2024
- Study completion20 Jan 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Uterine Cervical NeoplasmsStudies of the same condition, open and under way.
- More trials run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 317 participants (actual)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Huaiwu Lu, Study director, The Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06897306
- Sponsor's protocol ID
- SYSKY-2025-057-01
- Status last verified
- Feb 2025
- First submitted
- 6 Feb 2025
- Last updated
- 26 Mar 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Mar 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Surgery Significantly Improves the Prognosis of Locally Advanced Gastric-type Endocervical Adenocarcinoma: a Population-based Cohort Study
- ClinicalTrials.gov ID
- NCT06897306
- Acronym / sponsor ID
- SYSKY-2025-057-01
- Keywords
- Uterine Cervical Neoplasms, cervical cancer, Gastric - type Mucinous Adenocarcinoma, surgery
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 317 participants (actual)
- Lead sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityUniversity, hospital or other
- Study start
- 1 Oct 2024 (actual)
- Primary completion
- 1 Nov 2024 (actual)
- Study completion
- 20 Jan 2025 (actual)
- First posted
- 26 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to collect data of patients with Gastric-type Endocervical Adenocarcinoma from the SEER database, analyze the related prognostic factors and treatment patterns of Gastric-type Endocervical Adenocarcinoma, and explore the impact of surgical treatment on the prognosis of locally advanced Gastric-type Endocervical Adenocarcinoma.
Detailed description
This study aims to collect data of patients with Gastric - type Endocervical Adenocarcinoma from the SEER database, analyze the related prognostic factors and treatment patterns of patients with Gastric - type Endocervical Adenocarcinoma, and explore the impact of surgical treatment on the prognosis of locally advanced Gastric - type Endocervical Adenocarcinoma.
Study subjects: Patients diagnosed with Gastric - type Endocervical Adenocarcinoma were identified using the SEER database and SEER*Stat 8.4.2 software. The search scope was the "SEER Research Plus Data, 17 Registries, Nov 2021 sub (2000 - 2019)" database, and the screening criteria included "Site and Morphology, Analytic Behavior Recode = Malignant" and "Site and Morphology, ICD - O - 3 / WHO 2008 Recode Site = Cervix". Patients with cervical Gastric - type Endocervical Adenocarcinoma were selected from the database.
Outcome measures: Overall survival (OS): The time from diagnosis to death of the patient.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- The Surveillance, Epidemiology, and End Results (SEER) database is a comprehensive source of population - based cancer incidence and survival data in the United States. The population covered by the SEER database is diverse and representative of the broader U.S. population. It includes individuals from various racial and ethnic backgrounds, age groups, and geographic regions. The data are collected from 17 population - based cancer registries, which cover approximately 28% of the U.S. population. This allows for the analysis of cancer - related outcomes and trends across different demographic and socioeconomic groups, providing valuable insights into the burden of cancer and the effectiveness of cancer - related interventions in a population - based setting.
Key inclusion criteria (1 listed)
- Patients diagnosed with Gastric - type Endocervical Adenocarcinoma were identified using the SEER database and SEER*Stat 8.4.2 software. The search scope was the "SEER Research Plus Data, 17 Registries, Nov 2021 sub (2000 - 2019)" database. The screening criteria included "Site and Morphology, Analytic Behavior Recode = Malignant" and "Site and Morphology, ICD - O - 3 / WHO 2008 Recode Site = Cervix". Patients with Gastric - type Endocervical Adenocarcinoma in the database were selected.
Key exclusion criteria (1 listed)
- Patients with a survival time of 0 or unknown.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| surgeryThe patient underwent surgery. | Procedure or surgery | – |
Primary outcome
Overall survival (OS)
Time frame: The time from diagnosis to death of the patient，Assessed up to 227 months
The time from diagnosis to death of the patient.
1 secondary outcome
Vital status recode(study cutoff used)
Time frame: up to 227 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Mar 2025.
Related trials for Uterine Cervical Neoplasms
Recruiting
Use Misoprostol to Optimize Prevention of Cervical Cancer
Cervical Cancers
RecruitingObservational study
Role of Liquid Biopsies in HPV-associated Cancer Treatment Monitoring
Cervical Cancer, Cervical Dysplasia
RecruitingPhase 4
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
Cervical Cancer
RecruitingObservational study
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
Endometrial Cancer, Cervical Cancer
RecruitingPhase 1
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Ovarian Neoplasms, Endometrial Neoplasms
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Huaiwu Lu study director
The Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Uterine Cervical Neoplasms and Surgery, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall survival (OS) (time frame: The time from diagnosis to death of the patient，Assessed up to 227 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Mar 2025.